Whooping cough vaccination in adolescents and adults. Update;Vacunación anti-tos ferina de los adolescentes y adultos. Puesta al día

Vacunas

Volumn 8, Issue 1, 2007, Pages 38-47

  Salleras, L ^a,b   Bayas, J M ^a   Calbo, F ^a   Campins, M ^a   Castrodeza, J ^a   Cerrillo, A ^a   Conde, M ^a   Dominguez A ^a   Dominguez V ^a   Forcada, J A ^a   Gil, A ^a   De Juanes, J R ^a   Saenz, M C ^a  

^a Salud Pública e Higiene ^*  (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PERTUSSIS VACCINE;

ADOLESCENT; ADULT; CHILD NUTRITION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG USE; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; INCIDENCE; MORBIDITY; PERTUSSIS; PRACTICE GUIDELINE; PREVALENCE; REVIEW; TREATMENT INDICATION; VACCINATION;

EID: 37849044988     PISSN: 15769887     EISSN: 15788857     Source Type: Journal    
DOI: 10.1016/S1576-9887(07)73969-9     Document Type: Article

References (86)

1. Comité de Vacunas de la Sociedad Española de Medicina Preventiva, Salud Pública e Higiene. Vacunas. 2006;7 Suppl 1:1-173.
2. Centers for Disease Control. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55:1-44.
3. Centers for Disease Control. Preventing Tetanus, Diphtheria, and Pertussis Among Adults: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP) and Recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for Use of Tdap Among Health-Care Personnel. MMWR. 2006;55:1-33.
4. Centers for Disease Control. Recommended adult immunization schedule-United States, October 2006-September 2007. MMWR. 2006;55:Q1-Q4.
5. Centers for Disease Control. Recommended Immunization Schedules for Persons Aged 0 to 18 Years-United States, 2007. MMWR. 2007;55:Q1-Q4.
6. Forsyth K. Prevention of pertussis. Recommendations derived from the Second Global Pertussis Roundtable Meeting. Vaccine. 2006. [En prensa.]
7. Public Health Agency of Canada. An Advisory Committee Statment (ACS). National Advisory Committee on Immunization (NACI). Prevention of pertussis in adolescents and adults. Can Commun Dis Rep. 2003;29:1-9.
8. Halperin SA. Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United Status. Pediatr. Pediatr Infect Dis J. 2005;24:S141-6.
9. Edwards KM, Decker MD. Pertussis vaccine. En: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: WB Saunders; 2004.
10. Brown F, Greco D, Mastrantonio P, Salmaso S, Wasilak S. Pertussis Vaccine Trials. Dev Biol Stand. 1997;89:14-23.
11. Guris D, Strebel PM, Bardenheier B, Brennan M, Tachsjian R, Finch E, et al. Changing epidemiology of pertussis in the United States: Increasing reported incidence among adolescents and adults 1990-1996. Clin Infect Dis. 1999;28:1230-7.
12. a ed. Barcelona: Masson; 2003. p. 139-62.
13. Salleras L. Vacunaciones del adolescente. En: Salleras L, editor. Vacunaciones preventivas. Barcelona: Masson; 2003. p. 931-46.
14. a ed. esp. Madrid: Acindes; 2007. p. 1411-36.
15. World Health Organization. Informal consultation on the control of pertussis with whole cell and acellular vaccines. Geneva, 1999. WHO/V&B/99.03
16. Wirsing von König CH, Postels-Multani S, Bock HL, Schmitt H. Pertussis in adults: frecuency of transmisión after household exposure. Lancet. 1995;346:1326-9.
17. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. BMJ. 1988;296:612-4.
18. He Q, Viljanen MK, Nikkari S, Lyytikainen R, Mertsola J. Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis. 1994;170:873-7.
19. Lugauer S, Heininger U, Cherry JD, Stehr K. Long-term clinical effectiveness of an acellular component vaccine and a whole-cell pertussis component vaccine. Eur J Pediatr. 2002;161:142-6.
20. Grimpel E, Begue P, Anjak I, Njamkepo E, François P, Guiso N. Longterm human serum antibody responses after immunisation with whole cell pertussis vaccine in France. Clin Diagn Lab Immunol. 1996;3:93-7.
21. Salmaso S, Mastrantonio P, Tosí AE, et al. Sustained efficacy during the first six years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics. 2001;108:E81.
22. Guiso N, Begue P, Cohen R, et al. Comparison of pertussis antibody levels in children up to 5 years of age primed at 2, 3, 4 months and boostered in a second year of life with either DTPa or DRPw based combination vaccines in France [abstract 62]. 40th ICAAC; Sept 17-20 2000; Toronto, Canada.
23. Cherry JD. Epidemiology of pertussis. Pediatr Infect Dis J. 2006;25:361-2.
24. Wheeler JG, Simmons AL. Pertussis update. Pediatr Infect Dis J. 2005;24:829-30.
25. Greenberg DP. Pertussis in adolescents: increasing incidence brings attention to the need for booster immunization of adolescents. Pediatr Infect Dis J. 2005;24:721-8.
26. Yeh SH, Mink CAM. Shift in the Epidemiology of Pertussis Infection: An Indication for Pertussis Vaccine Boosters for Adults? Drugs. 2006;66:731-41.
27. Halperin SA. The control of pertussis-2007 and beyond. N Engl J Med. 2007:356:110-3.
28. Galanis E, King AS, Varughese P, Halperin SA. Changing epidemiology and emerging risk groups for pertussis. Can Med Assoc J. 2006;174:451-2.
29. Orenstein WA. Pertussis in adults: epidemiology, signs, symptoms and implications for vaccination. Clin Infect Dis. 1999;28 Suppl 2:S147-50.
30. Herwaldt LA. Pertussis in adults. What adults need to know. Arch Intern Med. 1991;151:1510-2.
31. Edwards KM. Pertussis in older children and adults. Advan Ped Infect Dis. 1998;13:49-77.
32. Keitel WA, Edwards KM. Pertussis in adolescents and adults: Time to reimmunize. Semin Resp Infect. 1995;10:51-7.
33. Yih WK, Lett SM, Des Vignes FN, Garrison KM, Sipe PL, Marchant CD. The increasing incidente of pertussis in Massachusetts adolescents and adults. J Infect Dis. 2000;182:1409-16.
34. Strebbel P, Nordin J, Edwards K, Junt J, Besser J, Bruts S, et al. Population based incidence of pertussis among adolescents and adults. Minesota 1995-1996. J Infect Dis. 2001;183:1353-9.
35. Nenning ME, Shinefield HR, Edwards KM, Black SB, Fireman BH. Prevalence and incidence of adult pertussis in an urban population. JAMA. 1996;275:1672-4.
36. Miller E, Fleming DM, Ashworth LA, Mabbett DA, Vurdien JE, Elliott TS. Serological evidence of pertussis in patients presenting with cough in general practice in Birmingham. Comun Dis Public Health. 2000;3:132-4.
37. Gilberg S, Njamkepo E, Parent du Chatelet I, et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J Infect Dis. 2002;186:415-18.
38. Roberston PW, Goldberg H, Jarvie BH, Smith DD, Whybin LR. Bordatella pertussis infection: a cause of persistent cough in adults. Med J Aust. 1987;146:522-5.
39. Wright SW, Edwards KM, Decker MD, Zeldin M. Pertussis infection in adults with persistent cough. JAMA. 1995;273:1044-6.
40. Schmitt-Grohe S, Cherry JD, Heininger U, Überall MA, Pineda E, Stehr K. Pertussis in German adults. Clin Infect Dis. 1995;21:860-6.
41. Rosenthal S, Strebel P, Cassiday P, Sanden G, Brusuelas K, Wharton M. Pertussis infection among adults during the 1993 outbreak in Chicago. J Infect Dis. 1995;171:1650-2.
42. Jansen DI, Gray GC, Putnam SD, Lynn F, Meade BD. Evaluation of pertussis in US Marine Corps tranees. Clin Infect Dis. 1997;25:1099-1107.
43. Wright SW. Pertussis infection in adults. South Med J. 1998;91:702-8.
44. Mink CM, Cherry JD, Christenson P, et al. A search of Bordetella pertussis infection in university students. Clin Infect Dis. 1992;14:464-71.
45. Birkebaek NH, Kristiansen M, Seefeldt T. Bordetella pertussis and chronic caugh in adults. Clin Infect Dis. 1999;29:129-42.
46. Sensilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis. 2001;32:1691-7.
47. Campins M, Moraga FA. La tos ferina en el adolescente y el adulto. Epidemiología e implicaciones para la vacunación. Med Clin (Barc). 2000;114:661-4.
48. Gimpel E, Baron S, Levy-Bruhl D, Garnier JM, N'Jamkepo, Guiso N, et al. Influenza of vaccination coverage on pertussis transmission in France. Lancet. 1999;354:1599-700.
49. Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini CH, Jennings CH, et al. Infant pertussis: Who was the source? Pediatr Infect Dis J. 2004;23:985-9.
50. Deville JG, Cherry JD, Christenson PD, Pineda E, Leach CT, Kuhts T. Frequency of unrecognized Bordetella pertussis infection in adults. Clin Infect Dis. 1995;21:639-42.
51. Izurieta H, Kenion TA, Strebel PM, Baughman AL, Shulman ST, Wharton M. Risk factors for pertussis in young infants during an outbreak in Chicago in 1993. Clin Infect Dis. 1996;22:503-7.
52. Black S. Epidemiology of pertussis. Pediatr Infect Dis J. 1997;16:S85-9.
53. Wirsing von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet. 2002;2:744-50.
54. Romero M, Domínguez A, Cardeñosa N, Carmona G, Codina G, Fuentes M and the Catalonia Pertussis Working Group. Detection of cases of pertussis by a surveillance programme: revaccination concerns. 5th World Congreso on Vaccines, Immunization and Immunotherapy (WCVII 2006). Montreal (Canadá), 6-9 november 2006, poster P-1.
55. th World Congress of the World Society for Pediatric Infectious Diseases (WSPID). Varsovia (Poland), september 1-4, 2005.
56. Kowalkiz F, Barbosa AP, Fernández VR, Carvalho PR, Avila-Agüero ML, Goh DYT, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Ped Infect Dis J 2007;26:238-42.
57. Gil A, Oyaguez J, Carrasco P, González A. Hospital admission for pertusis in Spain 1995-1998. Vaccine. 2001;19:4791-4.
58. Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics. 1995;96:548-57.
59. Van der Wielen M, Van Damme P, Joosens E, François G, Meurice F, et al. A randomised controlled trial with a diphteria-tetanus acellular pertussis (dTpa) vaccine in adults. Vaccine. 2000;18:2075-82.
60. Bartels I, Jungert J, Lugauer S, Stehr K, Heininger Ll. Immunogenicity and reactogenicity of a single dose of a diphteria-tetanus-acellular pertussis component vaccine (DtaP) compared to a diphteria-tetanus toxoid (Td and a diphteria toxoid vaccine (d) in adults. Vaccine. 2000;19:3137-45.
61. McIntyre PF, Turnbull FM, Egan AM, Burgess MA, Wolter JM, Schuerman LM. High levels of antibody in adults three years after vaccination with a reduced antigen content diphteria-tetanus-acellular pertussis vaccine. Vaccine. 2004;23:380-5.
62. Le T, Cherry JD, Chang SJ, Knoll MD, Lee ML, Barenkamp S, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis. 2004;190:535-44.
63. Zepp F, Knuf M, Habermehl P, Mannhardt-Laakmann W, Howe B, Friedland LR. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr. 2006;149:603-610.
64. Chan SH, Tan PT, Han HH, Bock HL. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults. Singapore Med J. 2006;47:286-90.
65. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet. 2006;367:1926-36.
66. Ward JI, Cherry JD, Chang SJ, Partridge S, Keitel W, Edwards K. Bordetella pertussis Infections in Vaccinated and Unvaccinated Adolescents and Adults, as Assessed in a National Prospective Randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis. 2006;43:151-7.
67. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353:1555-63.
68. Hewlett EL, Edwards KM. Pertussis. Not just for kids.N Engl J Med. 2005;352:1215-22.
69. De Serres G, Duval B. Pertussis vaccination beyond childhood. Lancet. 2005;365:1015-6.
70. Robbins JB, Schneerson R, Trollfors B, Sato H, Sato Y, Rappuoli R, et al. The diphteria and pertussis components of diphteria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis. 2005;191:81-8.
71. Keitel WA. Cellular and acellular pertussis vaccines in adults. Clin Infect Dis. 1999;28 Suppl 2:S118-23.
72. Decker MD, Edwards KM. Acellular pertussis vaccines. Ped Clin North America. 2000;47:309-35.
73. Keitel WA, Edwards KM. Acellular pertussis vaccines in Adults. Infect Dis Clin North America. 1999;13:83-94.
74. Halperin SA, Smith B, Rusell M, Hasselback P, Guasparini R, Skowronski D, et al. An adult formulation of a five component acellular pertussis vaccine combined with diphteria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine. 2000;18:1312-9.
75. Halperin SA. Pertussis - A disease and vaccine for all ages. N Engl J Med. 2005;353:1615-7.
76. Wirsing von Konig CH, Campins-Marti M, Finn A, Guiso N, Mertsola J, Liese J. Pertussis immunization in the global pertussis initiative European region: recommended strategies and implementation considerations. Pediatr Infect Dis J. 2005;5 Suppl:S87-92.
77. Halperin SA. Prevention of perturssis across the age spectrum throught the use of the combination vaccines Pentacel and Azacel. Expert Opin Biol Ther. 2006;6:807-21.
78. Brooks DA, Clover R. Pertussis infection in the United States: role for vaccination of adolescents and adults. J Am Board Fam Med. 2006;19:603-11.
79. Halperin SA. Recommendations of an adolescents dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: reassurance for the future. J Pediatr. 2006;49:589-91.
80. Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics. 2005;115:1675-84.
81. Heininger U, Cherry JD. Pertussis immunisation in adolescents and adults-Bordetella pertussis epidemiology should guide vaccination recommendations. Expert Opin Biol Ther. 2006;6:685-97.
82. Muñoz FM. Pertussis in infants, children and adolescents: diagnosis, treatment and prevention. Semen Pediatr Infect Dis. 2006;17:14-9.
83. Campins M, Cheng HK, Forsyth K, Guiso N, Halperin S, Huang LM, et al. Recommendations are needed for adolescent and adult pertussis immunization: rationale and strategies for consideration. Vaccine. 2001;20:641-6.
84. Forsyth KD, Campins-Marti M, Caro J, Cherry JD, Greenberg D, Guiso N, et al. New pertussis vaccination strategies beyond infancy: Recommendations by the Global Pertussis Initiative. Clin Infect Dis. 2004;39:1802-9.
85. Halperin SA, Sweet L, Baxendale D, Neatby A, Rykers P, Smith B, et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine? Pediatr Infect Dis J. 2006;25:195-200.
86. Comité Asesor de Vacunas de la Asociación Española de Pediatría. Calendario vacunal de la Asociación Española de Pediatría: recomendaciones 2005. An Pediatr (Barc). 2005;62:158-60.